18 F-FDG PET/CT predicts survival after 90 Y transarterial radioembolization in unresectable hepatocellular carcinoma
European journal of nuclear medicine and molecular imaging(2017)
摘要
Purpose To compare the value of pretreatment functional and morphological imaging parameters for predicting survival in patients undergoing transarterial radioembolization using yttrium-90 ( 90 Y-TARE) for unresectable hepatocellular carcinoma (uHCC). Methods We analysed data from 48 patients in our prospective database undergoing 90 Y-TARE treatment for uHCC (31 resin, 17 glass). All patients underwent 18 F-FDG PET/CT and morphological imaging (CT and MRI scans) as part of a pretherapeutic work-up. Patients did not receive any treatment between these imaging procedures and 90 Y-TARE. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were used to assess the prognostic value of 18 F-FDG PET/CT metabolic parameters, including SUV max , tumour-to-liver (T/L) uptake ratio and SUV mean of healthy liver, and morphological data, including number and size of lesions, portal-venous infiltration (PVI). Relevant prognostic factors for HCC including Child-Pugh class, Barcelona Clinic Liver Cancer (BCLC) stage, tumour size, PVI and serum AFP level were compared with metabolic parameters in univariate and multivariate analyses. Results The median follow-up in living patients was 16.2 months (range 11.4–50.1 months). Relapse occurred in 34 patients (70.8%) at a median of 7.4 months (range 1.4–27.9 months) after 90 Y-TARE, and relapse occurred in 24 of 34 patients (70.8%) who died from their disease at a median of 8.1 months (range 2.2–35.2 months). Significant prognostic markers for PFS were the mean and median lesion SUV max (both P = 0.01; median PFS 10.2 vs. 7.4 months), and significant prognostic markers for OS were the first quarter (Q1) cut-off values for lesion SUV max and T/L uptake ratio (both P = 0.02; median OS 30.9 vs. 9 months). The multivariate analysis confirmed that lesion SUV max and T/L uptake ratio were independent negative predictors of PFS (hazard ratio, HR, 2.7, 95% CI 1.2–6.1, P = 0.02, for mean SUV max ; HR 2.6, 95% CI 1.1–5.9, P = 0.02, for median SUV max :) and OS (HR 3.2, 95% CI 1–10.9, P = 0.04 for Q1 SUV max ; HR 3.7, 95% CI 1.1–12.2, P = 0.03, for Q1 T/L uptake ratio), respectively, when testing with either the BCLC staging system or serum AFP level. Conclusion Lesion SUV max and T/L uptake ratio as assessed by 18 F-FDG PET/CT, but not morphological imaging, were predictive markers of survival in patients undergoing 90 Y-TARE for uHCC.
更多查看译文
关键词
FDG PET/CT,Hepatocellular carcinoma,Imaging,Survival,TARE
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要